Literature DB >> 23919354

Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material.

Cédric Mazoyer1, Jérémy Carlier, Alexandra Boucher, Michel Péoc'h, Catherine Lemeur, Yvan Gaillard.   

Abstract

We report the case of a man who died twelve hours after ingesting powdered iboga root, commonly taken for its stimulant and hallucinogenic properties. Ibogaine and ibogamine were quantified in the powder ingested and the victim's body fluids by GC-MS/MS after liquid-liquid extraction (Toxi-tubes A(®)). The concentrations of ibogaine measured in the blood samples taken at the scene and in the peripheral blood, urine, and gastric fluid samples taken during the autopsy were 0.65, 1.27, 1.7, and 53.5 μg/mL, while the iboga content in the powder was 7.2%. Moreover, systematic toxicological analyses of biological samples showed the presence of diazepam and methadone in therapeutic concentrations. Death was attributed to the ingestion of a substantial quantity of iboga in the context of simultaneous methadone and diazepam consumption.
© 2013 American Academy of Forensic Sciences.

Entities:  

Keywords:  Tabernanthe iboga; forensic science; forensic toxicology; gas chromatography-tandem mass spectrometry; ibogaine; ibogamine; poisoning

Mesh:

Substances:

Year:  2013        PMID: 23919354     DOI: 10.1111/1556-4029.12250

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  6 in total

1.  Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700.

Authors:  Camille Richeval; Jean-Michel Gaulier; Ludovic Romeuf; Delphine Allorge; Yvan Gaillard
Journal:  Int J Legal Med       Date:  2018-11-15       Impact factor: 2.686

Review 2.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

Review 3.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

Review 4.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

5.  "Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report.

Authors:  Lorenz Breuer; Burkhard S Kasper; Bernd Schwarze; Juergen M Gschossmann; Johannes Kornhuber; Helge H Müller
Journal:  J Med Case Rep       Date:  2015-10-31

6.  Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Lena Rubi; Daniel Eckert; Stefan Boehm; Karlheinz Hilber; Xaver Koenig
Journal:  Cardiovasc Toxicol       Date:  2017-04       Impact factor: 3.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.